证券代码：300289 证券简称：利德曼 公告编号：2025-027 北京利德曼生化股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 | 产品 类型 | 金额 （万 | 起息 | | 到期日 | | 预计年化收益率 | 赎回本金 | 实际收 益（万 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 元） | 日 | | | | | （万元） | 元） | | 保本 浮动 | 8,000 | 2025 年 1 | 月 | 2025 7 月 | 年 7 | 1.3%-2.51% | 8,000 | 100.12 | | 收益 | | | | | | | | | | 公司 型 | | 6 日 | | 日 | | | | | | 交易方 华夏银行 股份有限 | | | | | | | | | | 名称 结 构 性 存 款 | | | | | | | | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")于 2025 年 3 月 4 日召开第 ...

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

Group 1 - The core business of Lidman includes research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1] - The company has received multiple accolades, including "National High-tech Enterprise" and "Beijing Specialized and Innovative Enterprise" [1] - As of the first quarter of 2025, Lidman reported a revenue of 78.91 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1.25 million yuan, a year-on-year increase of 53.73% [1] Group 2 - The latest closing price of Lidman was 5.22 yuan, with a market capitalization of 2.84 billion yuan and a price-to-book ratio of 1.71, marking a new low in 79 days [1] - The company is held by three institutions, with a total holding of 263.08 million shares valued at 1.24 billion yuan [1] - The industry average price-to-earnings ratio (PE) is 50.99, while Lidman's PE (TTM) is -38.56, indicating a significant divergence from industry norms [2]

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Lidman Biochemical Co., Ltd, including its stock price, market capitalization, and financial results for Q1 2025 [1] - On June 3, Lidman closed at 5.05 yuan, up 1.41%, with a latest price-to-book ratio of 1.65, marking a new low in 49 days and a total market value of 2.747 billion yuan [1] - The company experienced a net outflow of main funds amounting to 8.4668 million yuan on June 3, with a total outflow of 25.8327 million yuan over the past five days [1] Group 2 - Lidman specializes in the research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials, with key products including biochemical diagnostic reagents and automated chemiluminescence immunoassay analyzers [1] - The company has received multiple accolades, including "National High-tech Enterprise" and "Beijing Specialized and New Small and Medium-sized Enterprises," and has been recognized as a leading enterprise in the Beijing biopharmaceutical industry [1] - The latest financial report for Q1 2025 shows that the company achieved operating revenue of 78.9087 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1.25172554 million yuan, a year-on-year increase of 53.73%, with a gross sales margin of 53.56% [1] Group 3 - The price-to-earnings (P/E) ratio for Lidman is reported at -37.30 (TTM) and -36.58 (static), with a price-to-book ratio of 1.65 and a total market capitalization of 2.747 billion yuan [2] - The industry average P/E ratio is 50.80 (TTM) and 49.07 (static), with an average price-to-book ratio of 4.67 and a total market capitalization of 108.36 billion yuan [2] - The industry median P/E ratio stands at 36.71 (TTM) and 36.84 (static), with a median price-to-book ratio of 2.48 and a total market capitalization of 50.19 billion yuan [2]

证券代码：300289 证券简称：利德曼 公告编号：2025-026 北京利德曼生化股份有限公司 关于子公司重新签订房屋租赁合同暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 1、北京利德曼生化股份有限公司（以下简称"公司"）全资子公司广 州利德曼医疗科技有限公司（简称"广州利德曼"）于 2021 年 3 月 1 日与 广州开发区控股集团有限公司（简称"广开控股"）签订《房屋租赁合同》， 并与广州凯云智慧服务有限公司（简称"凯云服务"）签订了《物业管理 服务合同》，内容详见公司在巨潮资讯网（http://www.cninfo.com.cn）披 露的《关于全资子公司重新签订房屋租赁合同暨关联交易的公告》（公告 编号：2021-019）以及后续披露的《关于重新审议全资子公司房屋租赁 暨关联交易的公告》（公告编号：2024-007）。 2、根据所在园区最新的租赁政策，广州利德曼于近日与广开控股重 新签订《房屋租赁合同》，与广开控股委托的物业管理服务公司广州凯云 发展股份有限公司（简称"凯云发展"）签订《加速器园区管理服务合同》。 ...

Core Viewpoint - Lidman Biochemical Co., Ltd. is experiencing a decline in revenue and profit, with a significant net outflow of funds, indicating potential challenges in the market [1][2]. Company Overview - Lidman specializes in the research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1]. - The company's main products include biochemical diagnostic reagents, immunodiagnostic reagents, and automated chemiluminescence immunoassay analyzers [1]. - Lidman has received multiple accolades, including "National High-tech Enterprise" and "Beijing Specialized and Innovative Enterprise" [1]. Financial Performance - For Q1 2025, Lidman reported revenue of 78.91 million yuan, a year-on-year decrease of 16.61% [1]. - The net profit for the same period was -1.25 million yuan, reflecting a year-on-year increase in losses of 53.73% [1]. - The gross profit margin stood at 53.56% [1]. Market Position - As of May 27, Lidman's stock closed at 4.98 yuan, with a market capitalization of 2.709 billion yuan and a price-to-book ratio of 1.63 [1]. - The company has seen a net outflow of 3.4978 million yuan in principal funds on May 27, with a total outflow of 7.7543 million yuan over the past five days [1]. Industry Comparison - Lidman's PE (TTM) ratio is -36.79, while the industry average is 49.11, indicating a significant disparity in valuation metrics [2]. - The industry median PE (TTM) is 35.89, suggesting that Lidman is underperforming compared to its peers [2].

Group 1 - The core viewpoint of the news is that Lidman Biochemical Co., Ltd. is experiencing a decline in revenue and profit, with a significant drop in stock performance and net outflow of funds [1] - As of May 20, Lidman’s stock closed at 5.04 yuan, up 1.61%, with a latest price-to-book ratio of 1.65, marking a 40-day low and a total market capitalization of 2.742 billion yuan [1] - In terms of fund flow, on May 20, Lidman saw a net outflow of 3.714 million yuan, with a total outflow of 7.288 million yuan over the past five days [1] Group 2 - The main business of Lidman includes research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1] - The company’s key products consist of biochemical diagnostic reagents, immunodiagnostic reagents, and automated chemiluminescence immunoassay analyzers [1] - Recent performance data shows that in Q1 2025, Lidman achieved operating revenue of 78.9087 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1.25172554 million yuan, a year-on-year decline of 53.73%, with a gross profit margin of 53.56% [1] Group 3 - Lidman has received multiple accolades, including "National High-tech Enterprise," "Zhongguancun High-tech Enterprise," and recognition as a leading enterprise in the "G20 Project" for the Beijing biopharmaceutical industry [1] - The company was also recognized as a "Benchmark Enterprise in Intelligent Manufacturing" in Beijing for 2018 and received certification for "Digital Workshop" in 2022 [1]

Group 1 - The core viewpoint of the news is that Lidman Biochemical Co., Ltd. is experiencing a decline in revenue and profit, with a significant drop in stock price and market performance [1] - As of April 29, Lidman closed at 4.6 yuan, up 2.00%, with a latest price-to-book ratio of 1.51, marking a new low in 18 days, and a total market value of 2.502 billion yuan [1] - In terms of capital flow, on April 29, Lidman saw a net outflow of 2.7495 million yuan, with a total outflow of 1.6919 million yuan over the past five days [1] Group 2 - The main business of Lidman includes research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1] - The company's key products consist of biochemical diagnostic reagents, immunodiagnostic reagents, and automated chemiluminescence immunoassay analyzers [1] - Recent performance data shows that in Q1 2025, the company achieved operating revenue of 78.9087 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1,251,725.54 yuan, a year-on-year decline of 53.73%, with a gross profit margin of 53.56% [1] Group 3 - Lidman has received several accolades, including "National High-tech Enterprise," "Zhongguancun High-tech Enterprise," and recognition as a leading enterprise in the "G20 Project" for the Beijing biopharmaceutical industry [1] - The company was also recognized as a "Benchmark Enterprise in Intelligent Manufacturing" in Beijing for 2018 and received certification for "Digital Workshop" in 2022 [1] Group 4 - In comparison to industry averages, Lidman's PE (TTM) is -33.98, and its price-to-book ratio is 1.51, while the industry average PE is 47.74 and the average price-to-book ratio is 4.40 [2] - The industry median PE is 36.15, with a median price-to-book ratio of 2.28, indicating that Lidman is underperforming relative to its peers [2]

证券代码：300289 证券简称：利德曼 公告编号：2025-023 北京利德曼生化股份有限公司 第六届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）第六届监事会 第四次会议于 2025 年 4 月 24 日在北京市北京经济技术开发区兴海路 5 号公司二层会议室以通讯方式召开。本次会议通知于 2025 年 4 月 17 日以电子邮件方式向全体监事发出，与会的各位监事已知悉与所 审议事项相关的必要信息。本次会议由公司监事会主席林冠宇先生主 持，应出席本次会议的监事 3 名，亲自出席监事 3 名。本次会议的召 集和召开符合《公司法》及《公司章程》等相关法律法规的规定。经 全体监事审议，投票表决通过以下议案： 一、审议通过《关于公司 2025 年第一季度报告的议案》 北京利德曼生化股份有限公司 监 事 会 2025 年 4 月 24 日 监事会对公司 2025 年第一季度报告进行了审核，提出如下书面 审核意见：公司董事会编制和审议公司《2025 年第一季度报告》的 程序符合法律法规、中国证监会 ...

具体内容详见公司在巨潮资讯网(http://www.cninfo.com.cn)披露的 《2025 年第一季度报告》（公告编号：2025-024）。 证券代码：300289 证券简称：利德曼 公告编号：2025-022 北京利德曼生化股份有限公司 第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")第六届董事会第四 次会议于 2025 年 4 月 24 日在北京市北京经济技术开发区兴海路 5 号公 司二层会议室以通讯方式召开。本次会议通知于 2025 年 4 月 17 日以电 子邮件方式送达全体董事，与会的各位董事已知悉与所审议事项相关的 必要信息。本次会议由董事长尧子女士主持，应出席本次会议的董事 7 名，亲自出席会议的董事 7 名。公司监事和高级管理人员列席了本次会 议。本次会议的召集和召开符合《公司法》和《公司章程》等有关规定， 会议所形成的有关决议合法、有效。经全体董事审议，投票表决通过如 下议案： 一、审议通过《关于公司 2025 年第一季度报告的议案》 董事会认为公司 202 ...